0829 GMT - Bayer's strong start to the year and signs of a recovery in its pharmaceutical business suggests earnings expectations might have bottomed out, Goldman Sachs analysts say in a research note. Consensus earnings estimates on the German agricultural and pharma group could start to trend higher as the market gives credit to its cost-savings plan, the analysts say. Moreover, the risk-reward equation on litigation updates through 2025 looks more favorable, according to Goldman Sachs. Legal cases over Bayer's Roundup weedkiller have been a drag on its stock since it lost the first trial in 2018, the analysts say. Goldman Sachs raises its recommendation on Bayer to buy from neutral, and lifts its target price to 33 euros from 29.10 euros. Shares jump 4.9% to 26.55 euros. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
June 05, 2025 04:29 ET (08:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。